Does Effexor Decrease Appetite?
Yes, Effexor (venlafaxine) significantly decreases appetite in both adults and children, with treatment-emergent anorexia occurring 2-4 times more frequently than placebo across all studied conditions.
Evidence from FDA Drug Label
The FDA label provides the most authoritative data on this adverse effect 1:
Adult Patients
- Major Depressive Disorder: 8% of Effexor XR patients vs 4% placebo reported anorexia (2-fold increase)
- Generalized Anxiety Disorder: 8% vs 2% placebo (4-fold increase)
- Social Anxiety Disorder: 17% vs 2% placebo (8.5-fold increase) - the highest rate
- Panic Disorder: 8% vs 3% placebo (2.7-fold increase)
Discontinuation rates due to anorexia ranged from 0.4% to 1.0%, indicating that while common, the appetite suppression is usually tolerable enough that most patients continue treatment.
Pediatric Patients
The appetite effects are even more pronounced in children and adolescents 1:
- GAD and MDD (ages 6-17): 10% vs 3% placebo reported decreased appetite
- Social Anxiety Disorder (ages 8-17): 22% vs 3% placebo - a striking 7-fold increase
Critical caveat: The appetite suppression in pediatric patients led to clinically meaningful weight and height deficits. Children gained less weight than expected based on age- and sex-matched peers, with the effect being more pronounced in younger children (under 12 years) than adolescents 1.
Supporting Research Evidence
A 2024 systematic review and meta-analysis confirmed these findings, showing that venlafaxine significantly increased the risk of anorexia as a serious adverse event (risk ratio: 2.66,95% CI: 1.67-4.25) 2. The review also identified "decreased appetite" as one of the common non-serious adverse events.
Clinical Implications
Monitor weight and appetite systematically, especially:
- During the first 8-12 weeks of treatment when anorexia is most commonly reported
- In pediatric patients, where growth parameters should be tracked against normative data
- At higher doses, as venlafaxine has an ascending dose-response curve 3
- In patients with Social Anxiety Disorder, where the incidence is highest (17% in adults, 22% in children)
The appetite suppression appears dose-dependent and related to venlafaxine's dual mechanism - at lower doses it acts primarily as a serotonin reuptake inhibitor (similar to SSRIs which also cause nausea and appetite changes), while higher doses add norepinephrine reuptake inhibition 3.
This is not an off-label weight loss indication - the appetite decrease is an adverse effect that requires monitoring, particularly given the potential impact on growth in pediatric populations.